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ABSTRACT
Within the Cytochrome P450 class of enzymes, there are a group known as the “orphan”
cytochromes. The “orphan” classification comes from the poorly understood in vivo functionality
and substrate specificity. Cytochrome P450 4V2 (CYP4V2) is one of these “orphans” and
belongs to the CYP4 family. The CYP4 family is known for the omega oxidation of endogenous
fatty acids. This family is most commonly found on chromosome 1 (CYP4ABXZ). CYP4V2 is
unique in that its location is bound to chromosome 4 as discovered by Jiao in 2004. Mutations
within the CYP4V2 gene have been associated with the disease known as Bietti’s Crystalline
Dystrophy (BCD). BCD is an autosomal recessive disorder presenting with crystalline and lipid
deposits in the cornea and retina. Gian Bietti first reported the disease in 1937 in three patients,
and in 2004 Li and his research group identified the CYP4V2 gene to be the cause. The unknown
nature surrounding wild-type CYP4V2 is where this research study gets its purpose. To start
declassifying its “orphan” status, a method for the expression and purification of protein has
been developed and optimized to obtain protein for functional characterization and structural
biology studies. Preliminary binding data for wild-type enzyme has yet to be obtained, and a
crystal hit has been identified with further optimization required.
KEYWORDS: orphan cytochrome P450, enzyme, Bietti’s crystalline dystrophy, molecular
biology, expression, purification, protein crystallography
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CHAPTER 1 – INTRODUCTION

Section 1.1 Cytochrome P450
Cytochrome P450s (CYP) are a superfamily of heme proteins catalyzing a range of
oxidative reactions. The name P450 comes from the characteristic 450-nm absorption peak in its
reduced and carbon monoxide bound state (Raucy and Allen, 2001). The human genome encodes
for 57 different isozymes of CYPs each differentiated with a unique alphanumeric code denoting
which family and subfamily the protein belongs. A shared sequence identity >40% classifies the
cytochrome into the same family, >55% identity classifies it into the same subfamily, the final
number in code denotes the polypeptide chain (ex. CYP4V2, family 4, subfamily V, polypeptide
2) (Edson and Rettie, 2013). The interest in cytochrome P450s stems from their roles in many
biological processes. Cytochromes oxidize exogenous compounds, drugs, pollutants, and other
natural compounds, and endogenous chemicals including steroids, eicosanoids, and other
regulatory molecules. These proteins are ubiquitous and the need to understand their diverse
function has driven the field of research. Within the superfamily, there is a class called the
“orphan” cytochromes. They are given this distinction because their substrates and in vivo
functions are not understood well. (Raucy and Allen, 2001; Kelly et al., 2011; Edson and Rettie,
2013). This chapter will focus on the structure, redox partner, its catalytic capabilities, and the
CYP4 family involved with Bietti’s Crystalline Dystrophy (BCD).
Section 1.1.1 Structure. Overall, the structure of CYPs are highly conserved. The closer
to the active site, heme, the more conserved the structure becomes. Two helices, I and L, and the
β-bulge, are the most conserved due to their interactions with the heme ligand and conservation
of heme-thiolate chemistry, Figure 1. Regions not highly conserved are those that are involved
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with the substrate specificity of each isoform. Eukaryotic CYPs are usually membrane-bound to
the endoplasmic reticulum (ER). A short transmembrane helix (TRH) of about 20 amino acid is
what binds the folded protein to the ER. The TRH is not required for catalytic activity, and in
recombinant protein studies, is often not included in the insertion gene. There are different
conformations that CYPs can exhibit in the cell, Figure 2.

Figure 1. Crystal structure of Cytochrome 4B2 labelling all helices and showing the heme
ligand in red.
Shifting between these conformations allows for different substrates to bind to the active site
(Raucy and Allen, 2001; Ortiz de Montellano, 2015).
In the closed-state, CYPs exhibit a high amount of thermal mobility in the F and G
helices, indicating these structures are involved in the conformational shifts allowing substrates
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to enter the active site (Ortiz de Montellano, 2015). Once a substrate binds, the F and G helices
move to close the entry. The entryway to different CYPs can accommodate various sized
substrates. Once the substrate has entered, it is brought within 4-5 Å of the heme iron. Oxidation
of the substrate proceeds with the help of a redox partner that facilitates a series of electron
transfer reactions. The redox partner complexes loosely with the CYP complex allowing for
quick dissociation and a rapid enzymatic turnover (Ortiz de Montellano, 2015).

Figure 2. Depiction of Cytochrome P450 CYP2B4 in the open (PDB 1PO5) and closed (PDB
1SUO) conformations.
Section 1.1.2 Redox Partner. Oxidation of a substrate happens through the reduction of
nicotinamide adenine dinucleotide phosphate (NADPH) and a series of electron transfer
reactions (Ortiz de Montellano, 2015). The NADPH-cytochrome CYP oxidoreductase is one
such oxidation partner (POR), Figure 3. Similar to the CYP complex, POR is a membrane-bound
complex containing two flavin moieties, flavin adenine dinucleotide (FAD) and flavin
mononucleotide (FMN) (Ortiz de Montellano, 2015). NADPH is a two-electron donor, with CYP
heme being a one-electron acceptor. FAD accepts a hydride ion from NADPH and then funnels
the electrons one at a time to FMN. FMN then transfers the electrons to the CYP. This series of
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transfer reactions gives rise to oxidation of many different compounds. Focus will be put on the
oxidation of lipids for purposes here (Ortiz de Montellano, 2015).

Figure 3. Cartoon depiction of Cytochrome P450 in complex with the redox partner
Cytochrome P450 Reductase.
Section 1.1.3 Enzymatic Role. One of the more recent discoveries of CYP oxidative
power is the metabolism of arachidonic acid to form eicosanoid products. There are three main
sites for cytochrome P450 catalyzed for highly regioselective lipid oxidation: 1. ω/ω-1
hydroxylase, 2. mid-chain hydroxylases, and 3. epoxygenases (Ortiz de Montellano, 2015).
The ω/ω-1 hydroxylase catalyzes the addition of a hydroxy group at the terminal carbon
or near the terminal carbon to form 16-20-hydroxyeicosatetranoic acids (HETEs) (Ortiz de
Montellano, 2015). The hydroxylation of the terminal carbon is done mainly through the CYP4
enzyme (Ortiz de Montellano, 2015). The formation of terminal HETEs leads a variety of effects
in the body such as renal vasodilation, inhibiting adenosine triphosphate (ATP) activity in renal
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tubes, and promoting hypertension (Ortiz de Montellano, 2015). Further discussion of the CYP4
is provided in subsequent sections. Mid-chain hydroxylases form 5-, 8-, 9-, 11-, 12, and 15HETEs. Hydroxylation in the mid-chain carbon is mainly done through the CYP1 and CYP2
families (Ortiz de Montellano, 2015). Mid-chain HETES regulate aqueous humor excretion,
increases Na+ and K+ excretion in urine, and also promote neutrophil migration (Ortiz de
Montellano, 2015). Epoxygenases generate cis-/trans- epoxyeicosatrienoic acids (EETs). The
majority of CYPs that catalyze these transformations are from the CYP2. EETs function as
membrane receptors, activate GPCR pathways, and have shown anti-inflammatory properties.
(Ortiz de Montellano, 2015).
Section 1.1.4 Cytochrome P450 Family 4. As stated above, the CYP4 family is
responsible for the ω-oxidation of saturated and polyunsaturated fatty acids (PUFAs) forming
various HETEs. The energetic costs of hydroxylating the ω-carbon is greater than a substituted
internal carbon (Edson and Rettie, 2013). Another note of significance is the presence of
covalent heme binding. A glutamate residue is esterified to a methyl group on the heme ligand
(Henne et al., 2001). This is postulated to give the active site rigidity for substrate hydroxylation.
Genes encoding for CYP4 families are clustered on chromosomes 1, 4, and 19. The
orphan members of the CYP4 family are CYP4F22 and CYP4V2 (Kelly et al., 2011; Edson and
Rettie, 2013). CYP4V2 is a distant relative to the rest of the CYP4 family. Its sequence identity
is ~35%, under the usual cut-off for same family classification (Kelly et al., 2011). It is grouped
in with the other CYP4 family members because of its ability to hydroxylate the ω-carbon
similar to other CYP4 family members (Edson and Rettie, 2013). It has ubiquitous expression
with a large local expression in the eye. This protein has clinical relevance in that it is involved

5

with a rare ocular disease known as Bietti’s Crystalline Dystrophy (Kelly et al., 2011; Edson and
Rettie, 2013).

Section 1.2 Bietti’s Crystalline Dystrophy
Bietti’s Crystalline Dystrophy is a rare ocular disease first reported by Gian Bietti in 1937
(Garcia-Garcia et al., 2010; Kelly et al., 2011; Darki et al., 2019). BCD is a progressive disease
the manifests within the 2nd or 3rd decade of life. The disease has an initial clinical presentation
of white-yellow crystals in the retina and the cornea, Figure 4 (Garcia-Garcia et al., 2010).

Figure 4. Initial clinical presentation of BCD. Numerous white crystals can be seen throughout
the eye.
Near the end stages, central vision declines, night blindness develops, and the visual field
is hindered (Garcia-Garcia et al., 2010). The exact composition of these crystals is unknown, but
it has been speculated that they may be caused by abnormal lipid metabolism (Nakano et al.,
2014). Since its discovery in 1937, the cause for BCD has been discovered to be mutations
within the CYP4V2 gene (Garcia-Garcia et al., 2010). Genetic mapping has led to the discovery
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of more than 20 mutations believed to cause BCD. (Garcia-Garcia et al., 2010; Kelly et al., 2011;
Darki et al., 2019).
CYP4V2 has a large local expression in retinal tissues and metabolizes PUFAs (GarciaGarcia et al., 2010; Nakano et al., 2014). The outside segment of our photoreceptor cells contains
membrane disks rich in phospholipids esterified to docosahexaenoic acid (DHA) and other fatty
acids (Garcia-Garcia et al., 2010). This outer segment is shed to regenerate membrane disks
(Garcia-Garcia et al., 2010). The lipids from the disks are then take up by the retinal pigment
epithelium (RPE) cells. Once inside the RPE cells, the lipids are transferred to the inner segment
of photoreceptors where they are used to synthesize new disk membranes (Garcia-Garcia et al.,
2010). This exchange of lipid molecules coupled with the role of CYP4V2 in fatty acid
metabolism, and the abnormal metabolism of fatty acids gives some insight into how CYP4V2
may have a role in BCD (Garcia-Garcia et al., 2010; Nakano et al., 2014). However, the exact
lipids that are metabolized by CYP4V2 in this process are not known.
Bietti’s Crystalline Dystrophy can be classified into three main stages. Stage 1 is the
death of RPE cells with crystal deposits forming at the center of the retina. This stage appears
most commonly during the 2nd or 3rd decade of life (Kelly et al., 2011). The initial stage can be
asymptomatic, or it can develop so slowly that an accurate diagnosis is difficult (Garcia-Garcia
et al., 2010; Kelly et al., 2011). The presence of symptoms does not need to appear in both eyes
at the same time and can develop asymmetrically (Garcia-Garcia et al., 2010; Kelly et al., 2011).
Stage 2 has symptoms spreading from the center of the retina into the choriocapillaris with a
decrease in the number of crystal deposits where the more advanced stages of atrophy occur
(Garcia-Garcia et al., 2010; Kelly et al., 2011). Stage 3 is the most advanced with severe atrophy
the RPE and choriocapillaris (Garcia-Garcia et al., 2010; Kelly et al., 2011). There are little to no
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crystal deposits at this stage. Visual representation of the three stages is seen in Figure 5 (GarciaGarcia et al., 2010; Kelly et al., 2011).

Section 1.3 Objectives
This project was designed to begin declassifying the “orphan” status of CYP4V2. An
optimized method for expressing and purifying the protein must be determined to give enough
protein for substrate binding and metabolism studies. One original goal was to compare the wildtype CYP4V2 enzyme to four mutations that have been identified in connection with BCD. The
other main goal is to obtain an optimized crystal to elucidate the 3D structure.

Figure 5. (A) Stage 1 BCD presence of crystals apparent in the eye. (B) Stage 2 crystals begin
to disappear and RPE cells atrophy. (C) No crystal deposits and extensive atrophy of RPE and
choriocapillaris.
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CHAPTER 2 - MOLECULAR BIOLOGY – CLONING AND SITE-DIRECTED
MUTAGENESIS

The world of recombinant proteins has revolutionized biochemistry. Previously small
amounts of protein were purified from large samples of animal and plant tissue or large volumes
of biological fluids. This was an impractical method because of the sheer volume of material
needed for small recovery. With the introduction of recombinant technology, the new methods
allowed for expression and purification of “large” volumes of protein that could be used for
characterization and research while also revolutionizing the industrial and commercial sectors
(Rosano and Ceccarelli, 2014).
Recombinant technology is an area of study in which genetic material is enzymatically
manipulated through in vitro rearrangements (Rodriguez and Tait, 1983). At the basic level,
obtaining a recombinant protein is achieved through taking the target DNA, cloning it into a
desired expression vector, transforming it into a host cell (bacterial, insect, or mammalian),
induction, and then extraction (Rosano and Ceccarelli, 2014; Manz et al., 2015). As simple as the
process may seem, researchers may be left with low yields, protein inactivity, or failed growth.
This chapter focuses on the molecular cloning aspects of this project. Theory behind
molecular cloning techniques of cloning and site-directed mutagenesis will be introduced. This
provides a background to help those understand the processes used to clone the CYP4V2 gene
into a suitable vector and the background required to understand the process that is site-directed
mutagenesis.
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Section 2.1 Polymerase Chain Reaction
Section 2.1.1 Principles of Polymerase Chain Reaction. The in vitro technique known
as polymerase chain reaction (PCR) allows for the amplification of nucleic acid segments for
analysis and cloning. The entire reaction takes place in a 0.2 mL tube which is placed into a
thermocycler. The reaction tube contains: 1. DNA template, 2. DNA polymerases, 3. DNA
primers, 4. free nucleotides, and 5. buffer. The DNA template is the sample of DNA of interest to
be amplified. DNA polymerases are added to act as catalysts for complementary DNA synthesis.
DNA primers are oligonucleotide segments that are complementary to the target DNA. Two
different primers are used, a forward and reverse. Each primer anneals to one strand of doublestranded DNA (dsDNA). These primers are designed specifically for the target DNA and in such
a manner that they do not self-anneal. Free nucleotides in the form of deoxyribonucleotide
triphosphates (dNTPs) are added as the fuel for synthesis. These are depleted as the reaction
takes place. The final component is a buffer. Buffers are used to provide a suitable environment
for the polymerase to be efficient. In the thermocycler, there are three stages to the process of
replication (Manz et al., 2015).
Stage 1 – DNA Denaturation. The stage elevates the temperature of the reaction vessel
into the range of 95℃. The hydrogen bonds inside the dsDNA are disrupted and the previously
annealed DNA separates into two single-stranded DNA (ssDNA) segments. At this stage, the
polymerases are inactive (Manz et al., 2015).
Stage 2 – Primer Annealing. At this stage, the temperature drops between 50-60℃. This
temperature range is acceptable for the hydrogen bonds between the nitrogenous bases to anneal.
With the excess primer segments in solution, the two new ssDNA segments are prevented from
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reannealing with each other. One primer is designed to anneal to the 3’ end of ssDNA, and the
other primer anneals to the 5’ end (Manz et al., 2015).
Stage 3 – Primer extension. For this stage, the temperature is raised to around 72℃ which
is an optimal temperature for the near perfect reproduction of complementary DNA. The
polymerases synthesize the complementary DNA by incorporating matching dNTPs to the
template strand. Once the segment is complete, extension stops (Manz et al., 2015).
These three stages make up one complete cycle. A complete reaction usually consists of
20-35 cycles of repeated heating and cooling. The temperature at which each stage takes place
and the heating and cooling it takes to reach the temperatures is imperative to the success of
reaction. The amount of DNA present in the tube usually doubles with each cycle (Manz et al.,
2015).
Section 2.1.2 Rate of Amplification. In a perfect scenario, DNA concentration will
double with every cycle, leading to an exponential model of amplification. The theoretical
number of DNA molecules can be calculated by multiplying the initial number of DNA segments
in the vessel by the exponential function, 2n, where n is the number of cycles completed. Figure 6
shows the amount a single DNA complex is amplified over the first four cycles of PCR.
This is purely theoretical and the actual number of copies at the end of the reaction is less
due to a few factors. As the cycles repeat, the reagents in solution deplete. Another reason is the
introduction of errors by the polymerases leading to incorrect base pairing (Manz et al., 2015).

Section 2.2 Restriction Digest
One of the major discoveries in recombinant DNA technology is the presence of
restriction enzymes. Restrictions enzymes are endonucleases that cut both strands of DNA at the
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Figure 6. Theoretical amplification of the first four cycles of a PCR reaction. This image was
made by Enzoklop, CC BY-SA 3.0 <https://creativecommons.org/licenses/by-sa/3.0>, via
Wikimedia Commons, no changes were made.
same time along the sequence at specific sites. These cuts create small fragments of DNA that
can then be inserted into a vector and introduced into a host. There are two types of restriction
enzymes: Type I and Type II (Birge, 1981; Freifelder, 1987; Griffiths et al., 1993).
Type I enzymes are nonspecific. These enzymes are made up of nonidentical subunits of
high molecular weight (Birge, 1981; Freifelder, 1987). This enzyme creates nonspecific cuts
along the DNA complex at a randomly located location many base pairs away from the original
recognition sequence (Birge, 1981). Type II enzymes are specific restriction endonucleases that
makes two single-stranded cuts within the recognition sequence (Birge, 1981). There are two
types of cuts that can be made, flush or blunt cuts and cohesive cuts. Cohesive cuts are more
desired for cloning. For flush cuts, the enzyme makes a cut directly down the center of symmetry
of the recognition sequence. Cohesive cuts are made by placing nicks along the DNA complex in
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such a manner that a tail of nucleotides extends past the nick. This done on both strands creating
two tails of complementary sequences (Birge, 1981; Freifelder, 1987).
Type II restriction enzymes are important for cloning recombinant methodologies. PCR
products are digested with restriction enzymes that match the restriction enzymes used to digest
the vector of interest. This creates complimentary ends for the two to fuse together during the
ligation process.

Section 2.3 Ligation
With the formation of two complementary components, the target gene now needs to be
joined with the vector through a process called ligation. This process can be completed in vitro
or in vivo by the enzyme known as DNA ligase. DNA ligases are found readily in cells and
belong to a family of enzymes known as the nucleotidyl transferases (Çaǧlayan, 2019). These
enzymes repair DNA nicks by catalyzing the formation of a phosphodiester bond between a 5’
phosphate and 3’ hydroxyl group on adjacent nucleotides (Çaǧlayan, 2019). There are three main
steps in the ligation process. Step 1 involves the adenylation of the adenylation domain (AdD)
forming a DNA ligase-adenylate complex. Adenosine triphosphate (ATP) is cleaved to form
adenosine monophosphate (AMP), which is what binds to the AdD. In step 2, the DNA ligase
binds to the nick in the DNA strand at the oligonucleotide binding domain (OBD) and the AMP
is transferred to the 5’ phosphate nucleotide. This forms an intermediate 5’AMP with DNA. The
third, and final, step, DNA ligase catalyzes the reaction between the 5’-AMP and 3’OH releasing
AMP in the process (Çaǧlayan, 2019). This process is irreversible because of the release of
highly energetic pyrophosphate coupled with the AdD being adenylated, pushing the ligation
process forward. With the process of ligation complete, the gene of interest has been cloned into
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a suitable vector for transformation and expression, the final process to obtain a desired
recombinant protein (Rodriguez and Tait, 1983; Çaǧlayan, 2019).

Section 2.4 Mutations and Site-Directed Mutagenesis
Section 2.4.1 Mutations. Mutations in genetics are inherited changes in the observable
traits of an organism. At the molecular level, a mutation is an alteration in a base pairing, which
can cause a change in the amino acid sequence of a protein. Sometimes mutations can produce
the same amino acid by mutating to a different codon encoding for the amino acid. This section
will introduce different types of mutations and how they affect polypeptides (Birge, 1981).
The first type of mutation is a base substitution. This is mutation is the replacement of
one base with another (Birge, 1981). Specific type base substitutions are transition and
transversion (Birge, 1981). Transition mutations are exchanging one pyrimidine for another
pyrimidine or a purine for a purine (Birge, 1981). Transversion mutation replace pyrimidines for
purines and vice versa. These mutations are the easiest to visualize and think through but can be
difficult to detect in sequences. There are multiple codons that encode the same amino acids
because of the high redundancy in the genetic code (Birge, 1981). The codon “UUU” encodes
for the amino acid phenylalanine, so does the codon “UUC.” Missense mutations, a type of base
substitutions, are easier to detect. This mutation causes the original amino acid to be replaced
with another. “ACC” encodes for threonine, while “CCC” encodes for proline (Birge, 1981).
This mutation would be easy to visualize because replacement with proline has detrimental
effects in secondary and tertiary structure, especially in helices (Birge, 1981). The genetic code
encodes for three termination codons “UGA,” “UAA,” and “UAG.” The insertion of any of these
codons is called a missense mutation (Birge, 1981). When these codons are inserted into a
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coding sequence, early termination of polypeptide elongation occurs (Birge, 1981). This creates
a truncated protein altering activity (Birge, 1981).
Three other types of mutations are insertions, deletions, and frameshifts. Insertions and
deletions are inverse mutations (Birge, 1981). Deletions are the removal of base pairs from the
DNA, and insertions are the addition of base pairs in DNA. These can be single mutations or
multiple mutations. If these mutations occur in multiples of three, then this adds or eliminates an
amino acid from the polypeptide chain. If the mutation causes the insertion or deletion of a single
base pair, this induces a frameshift mutation. If the insertion or deletion shifts the reading frame,
the normal amino acid sequence is disrupted, forming gibberish proteins (Birge, 1981).
Section 2.4.2 Site-Directed Mutagenesis. Natural mutations can have serious effects on
polypeptide structure and function. For the purpose of research interests, the ability to introduce
mutations into a sequence of DNA is important for understanding their effects in hosts. The
introduction of site-directed mutagenesis (SDM) revolutionized the research world. SDM
methods can be either in vivo or in vitro. Synthetic oligonucleotide primers are designed such
that, for a single-base mutation, the primers are complementary to the DNA sequence except for
the mutated base. If the primers are designed correctly, they have no problem annealing to the
parent DNA. Figure 7 double-primer mutagenesis design with single mutation primer.

Figure 7. Cartoon depiction of double-primer mutagenesis with single-primer mutation. This
image was made by Rob Hunt, BY CC-SA 4.0, image not modified.
Single-primer designs create a heteroplasmid with one strand of DNA containing the
mutation, while the other strand is a parent strand. Double-primer designs create a new plasmid
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with the mutated base on both strands. Current SDM methods utilize the double-primer design
wherein two primers are designed that are complementary to the parent DNA and thus to each
other. This introduces the complication of primers self-dimerizing in solution which decreases
the efficiency of the reaction and could prevent mutagenesis completely. Alternative protocols
are developed to circumvent these complications and are commonplace in SDM (El-Gewely et
al., n.d.; Carter, 1986; Edelheit et al., 2009).

Section 2.5 Electrophoresis
The use of electrophoresis can be applied to many biomolecules including DNA/RNA,
proteins, and carbohydrates (Manz et al., 2015). Matrices for separation are usually done in gels
made by cross-linked polymers of either agar, agarose, or polyacrylamide (Stellwagen, 2009;
Manz et al., 2015).
Section 2.5.1 Theory of Electrophoresis. In the presence of an applied electric field,
charged molecules in a conductive medium will travel through a gel consisting of cross-linked
polymers. Conductive mediums are usually represented by the use of aqueous buffers that have
high salt content and a pH that charges the molecule either negatively or positively which
determines the flow of analytes to either the anode or cathode. Figure 8 shows the main principle
behind electrophoresis.
If using a gel, the cross-linked polymers act as molecular sieves that can filter out the
analyte based on sample size. Larger molecules are retarded more than smaller molecules, so
molecules with similar charge to mass ratio can still be separated out (Manz et al., 2015).
Section 2.5.2 Gel Electrophoresis Instrumentation. There are two main parts to the
electrophoresis instrumentation. First is the power supply, and the second is the chamber which
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the gel sits with an electrolyte buffer. Power supplies are set to deliver both low and high voltage
power. Electrodes are attached to the chamber and fashioned in such a way that they are
immersed in running buffer. The chamber can either be vertical or horizontal. The running buffer
is chosen to either have a high pH, creating negatively charged molecules, causing migration to
happen from cathode to anode. If the pH is low, then the opposite movement results. When
introducing sample into the gel, they are placed such that they migrate towards the electrode of
analyte charge (Manz et al., 2015).

Figure 8. Principle behind electrophoresis. Negatively charged analytes move towards the
cathode. Image by Jjw, CC BY-SA 3.0 <https://creativecommons.org/licenses/by-sa/3.0>, via
Wikimedia Commons, this image was not modified.
Section 2.5.3 Band Visualization. Sample analyte cannot be visualized under normal
conditions and must be treated. The most common method of visualizing bands is staining with
either fluorescent dyes, silver dyes, or Coomassie brilliant blue. A sample DNA ladder is runs in
tandem with the analytes. The DNA ladder is a mixture of defined base pair lengths which give a
standard set of molecular weights. The sample analytes can be visually inspected and compared
against the ladder to determine approximate number of base pairs in the sample. (Manz et al.,
2015).
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Section 2.6 Methodology
Section 2.6.1 Polymerase Chain Reaction. To start a polymerase chain reaction (PCR)
both the gene and the primers need to be diluted in water. On arrival from Thermo Fisher, the
gene contained about five micrograms (µg) of Kan R plasmid DNA. To this, 20 microliters (µL)
of water was added to make a 250 ng/µL solution. The forward primer arrived with a mass of
235.73 µg which corresponds to 32.04 nanomoles (nmol). To the primer tube, 1.282 mL of water
was added to create a 25 micromolar (µM) solution, tubes were then vortexed to create a
homogenous solution. All further dilutions of primers are provided in Table 1.

Table 1. Dilutions of Wild-Type Primers and Mutant Primers
Primer
Designation

Molecular Weight
(g/mol)

# of moles
present (nmol)

mL used for
dilution

Final Conc.
(µM)

Rvs 4V21
5882.89
30.05
1.22
24.63
Fwd F73L
5215
76.9
1.538
50
Rvs F73L
5162
78
1.56
50
Fwd I111T
5185
82.5
1.65
50
Rvs I111T
5203
52
1.04
50
Fwd T325I
4926
50.8
1.016
50
Rvs T325I
4793
61.7
1.234
50
Fwd H331P
5530
71.4
1.428
50
Rvs H331P
5468
61.8
1.236
50
1
Due to human error in initial calculations, Rvs 4V2 was incorrectly diluted to 24.63 µM
instead of 25 µM.
Once all dilutions were completed, PCR tubes can be set up. Two PCR tubes are run
together in case of one failing. In the following order, each tube received 35.5 µL of autoclaved
DI water, 1 µL CYP4V2 DNA, 1 µL 4V2 Fwd primer, 1 µL 4V2 Rvs primer, 1 µL dNTP
(deoxynucleotide triphosphate), 10 µL 5x GC buffer, and 0.5 µL Phusion Polymerase. The tubes
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are then placed in the PCR instrument. Method PCR2 was selected from the screen and the
instrument was allowed to run. Method PCR2 initial setup provided in Table 2.
Section 2.6.2 Site-Directed Mutagenesis. To obtain the mutations of CYP4V2, sitedirected mutagenesis is performed. Using the mutant primers listed in Table 3. and the Phusion
Mastermix PCR kit, the PCR tubes will be set up similarly to the wild-type PCR tubes. Twentythree microliters of DI autoclaved water, 25 µL of Phusion Mastermix, 0.5 µL forward mutant
primer, 0.5 µL reverse mutant primer, and 1 µL of CYP4V2 template DNA is added to a PCR
tube and run in duplicate using a modified PCR method. In step 2, the “mutant pcr” method,
change the temperature of the annealing step to match the Tm of the mutant primers. Tm of
primers given in Table 4 and are calculated using the calculator found on the Thermo Fischer
website.

Table 2. PCR Method for Veriti 96 Well Thermal Cycler Wild-Type Reactions.
Stage
Step
Temperature (℃)
Time (s)
1
2

1
1
2
3
1
2

3

98
30
98
10
53
30
72
60
72
120
4 Indefinitely

Section 2.6.3 Restriction Digest. Once PCR product was sequence verified, restriction
digest was performed next. To each tube the following was added: 1µL of Dpn1, 1 µL HindIII, 1
µL NdeI, and 5 µL of FD Buffer. When doing a digest of plasmid, Dpn1 is not added. Following
the addition of the restriction enzymes, the two tubes were placed in a New Brunswik Galaxy
170S incubator for thirty minutes to an hour.
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Section 2.6.4 DNA Gel Electrophoresis. After the PCR product has been obtained, a
DNA gel is used to determine if the PCR amplification worked. To make a gel, 1.5 g of agarose
solid is weighed out and transferred to a large beaker. 100mL of 1x TAE Buffer was poured in.
The entire beaker was taken to the microwave and heated in short 30 second bursts to dissolve
the agarose solid. The contents of the beaker start vigorously bubbling near the end, so the
beaker was watched through the microwave door, and heating was stopped if needed.
Periodically, the beaker was removed from the microwave to check if the solid dissolved. Once it
was dissolved, the hot beaker was carefully removed, and the contents were poured into a gel
runner. A well comb was placed on one end of the gel and the entire apparatus was allowed to
cool to room temperature on the counter. Once cooled down, it was moved into the refrigerator
to finish gelling.

Table 3. Primer Sequences for Site-Directed Mutagenesis.
Primer Designation
Primer Sequence2
Fwd F73L
GTCGTGAATTATTTCAG
Rvs F73L
CTGAAATAATTCACGAC
Fwd I111T
TTGAAGTGACTCTGACC
Rvs I111T
GGTCAGAGTCACTTCAA
Fwd T325I
GAGGTTGATATCTTTA
Rvs T325I
TAAAGATATCAACCTC
Fwd H331P
GTTTGAAGGTCCTGATAC
Rvs H331P
GTATCAGGACCTTCAAAC
2
Sequences read 5’ → 3’ with mutant base pair in red.
After the gelling process completes, the runner was removed, and the comb taken out.
The runner with the gel was placed into the Kodak BioMax QS710 electrophoresis chamber,
making sure to have the gel wells next to the black anode so they run towards the red cathode.
The chamber was filled with 1X TAE buffer to cover the gel. A DNA ladder was made to have a
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standard comparison. To 10 µL of DNA ladder 2 µL of EZ-Vision One visualization dye was
added. Five microliters of PCR product are mixed with 1 µL of EZ-Vision One. Ten microliters
of DNA ladder with dye was added into the first well and 5 µL of each PCR product with dye
was added to subsequent wells. The Bio Rad PowerPac™ Basic was turned on and the voltage set
to 120. The gel was allowed to run until the dye band reached about halfway through the gel.
Once the gel was finished, it was transferred to the Transilluminator for visualization. PCR
products in the wells fluoresced when placed in the Transilluminator.

Table 4. Annealing Temperatures of Mutant Primers.
Mutation
Annealing Temperature (℃)
F73L
50.5
I111T
56.0
T325I
46.1
H331P
55.2
Section 2.6.5 DNA Cleaning and Concentrating. After restriction digest, the tubes were
removed from the incubator. Using Zymo’s DNA Clean & Concentrator-5 kit DNA is
concentrated. The products from the two PCR tubes were combined into a 1.5 mL Eppendorf
tube. Binding buffer is added to the combined product in a 5:1 ratio for PCR product (e.g. For
100 µL of PCR product, 500 µL of binding buffer is added). The entire contents of the
Eppendorf tube were transferred to a Zymo-Spin™ column. The column was placed in a
thermoscientific mySPIN12 centrifuge and balanced with another column. The centrifuge was
set to spin at 10,000 rpm for thirty seconds. The eluate was discarded in a small beaker. 200 µL
of wash buffer was added to the column and centrifuged again at 10,000 rpm for thirty seconds.
The eluate was discarded, and the wash step was repeated once more. After discarding the
second eluate 10 µL of DNA elution buffer was added to the column and allowed to incubate at
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room temperature for one minute. After incubation, the column was transferred to a 1.5 mL
Eppendorf tube and centrifuged again for 30 seconds. The eluate here is the cleaned and
concentrated DNA.
Section 2.6.6 Plasmid Preparation. pCW CYP17A1 was provided as a gift through a
material transfer agreement with Dr Emily Scott. A single DH5α colony containing pCW 17A1
was selected and used to start a 5 mL LB culture. Using a Thermo Scientific Gene JET Plasmid
Miniprep kit, two 1.5 mL Eppendorf tubes, 1000 µL deliveries were made. The tubes were the
centrifuged for two minutes. The liquid layer was decanted off and another set of cell delivery
were made. This process was repeated once more. After the final centrifuge, the liquid was
completely decanted off and 250 µL of resuspension solution was added one tube and the cells
were resuspended and transferred to the other tube, and the cells were completely resuspended.
Two-hundred and fifty milliliters of Lysis solution was added to the tube and inverted a few
times. After inversion, 350µL of Neutralization solution was added and inverted a few times.
After inversion, the tube was placed in the centrifuged and allowed to spin for 5 minutes at an
rpm of 13,300. The supernatant solution was added to a Thermoscientific Gene JET spin column
and centrifuged for one minute. The eluant was poured off and 500 µL of wash solution was
added to the column and centrifuged for one minute. This wash step was repeated one time. After
washing, the column was transferred to an Eppendorf tube, 50 µL of elution buffer was added,
and it was allowed to incubate for two minutes. After incubation, it was centrifuged for two
minutes and the eluant was collected.
Section 2.6.7 Gel DNA Recovery Kit. Plasmid collected in Miniprep Kit was digested
and run in a DNA gel. To recover the Plasmid, a Zymoclean Gel DNA Recovery Kit was used.
Gel slices were removed that contained the completely digested DNA. In a 3:1 ratio of agarose

22

dissolving buffer to plasmid gel, the gel was dissolved in a tube. This was allowed to incubate at
37℃ until completely dissolved. The dissolved agarose gel was transferred to a zymo-spin
column and centrifuged for one minute at 13,300 rpm. Two-hundred microliters of buffer was
added, centrifuged, and washed again. Ten microliters of elution buffer are added to the column,
the column was transferred to an Eppendorf tube, and centrifuged for one minute.
Section 2.6.8 Sequencing Preparation. A single DH5α colony with pCW4V2 was
selected and a culture was grown in 5 mL of LB media overnight. Culture was treated the next
day according to Plasmid Preparation above. Using the eluant collected, 10 µL of plasmid was
removed and placed in a PCR tube. To every other tube, 5 µL of pCW Fwd primer was added,
and to the other tubes, pCW Rvs primer was added. The tubes were capped and wrapped in
parafilm to ensure safe delivery. Tubes were then sent GenScript for sequencing analysis.

Section 2.7 Results
The beginning of any expression project starts with molecular cloning. The CYP4V2
gene was designed and ordered from Invitrogen by Thermo Fischer Scientific and arrived in the
pMK-RQ vector backbone. To give ideal concentrations for PCR, the gene was diluted to an
initial concentration of 250 ng/µL to give a final concentration of ~5 ng/µL in the PCR tube. The
first attempt at PCR is highlighted in Figure 9. The first lane of the gel is the DNA ladder, the
next two lanes are of PCR product, the remaining five lanes are of digested pCW plasmid. All
lanes are visualized by adding a fluorescent dye, visible under a UV light source. The two lanes
of 4V2 gene are stuck in the well indicating either a large kb product or digestion with restriction
enzymes did not cleave the gene from the insert and the plasmid as a whole is sitting in the well.
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The intense fluorescence is a qualitative indication that there is replicated product. The lanes
with pCW17A1 being empty could indicate no DNA in solution.

Figure 9. Electrophoresis gel showing the first attempt at PCR of the CYP4V2 gene (lanes 2
and 3) with product of pCW17A1 digestion (lanes 4-8).
For attempt number two, the buffer used in the PCR tube was changed. The first reaction
utilized the fast digest (FD) buffer that came with the Phusion High Fidelity PCR kit, the
second reaction switched from FD buffer to GC buffer. After digestion, another DNA gel was
prepared and run. Lane one was DNA ladder, and the next two lanes were PCR product, Figure
10. This attempt had a successful replication and separation of the gene from the vector
backbone. A second digestion of the pCW17A1 was attempted. This time, there is clear
separation between 17A1 gene insert and the pCW backbone, which can be visualized in Figure
11. The bottom band is the gene insert and the top band is the vector backbone. The top band
was dissected, and the DNA was extracted from the gel using the Zymoclean Gel DNA Recovery
Kit.
Now that PCR product has been visualized and an empty plasmid backbone has been
obtained, the two needed to be ligated together to make the pCW4V2 vector. In the presence of
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ligase, the insert and plasmid are ligated together in a 3:1 ratio with 2.5 µL of ligase. After a
period of incubation, the presumed ligated DNA was transformed into DH5α cells, and plated
onto a lysogeny broth ampicillin (LB-amp) plate.

Figure 10. Banding present around the 15 kDa band of the DNA ladder representing the
CYP4V2 gene.
The plate was incubated and the next day colonies were observed. Three colonies were
picked, grown a small portion of LB media overnight, and the following day the DNA was
extracted from the cells. To confirm ligation worked, extracted DNA was sent to GeneScript for
sequence verification. All three colonies picked from the plate were empty, no DNA insert was
confirmed.

Figure 11. Successful digestion of pCW17A. Top band empty plasmid, bottom band 17A1
insert.
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Another PCR was completed with the same conditions as attempt number two, and
another ligation attempt was made. Cell transformation had an additional outgrowth step where
transformed competent cells are incubated with a small portion of LB media to increase the
number of cells. The cells were plated and left to incubate. Two plates were incubated for the
two PCR products run, one plate had one large colony and the second plate had no colonies,
plate one seen in Figure 12. The one large colony was picked and set for sequencing like the
previous attempt, sequencing results showed failed ligation again. Numerous attempts were
made with all ligation attempts to grow colonies on plates, with little to no success. If colonies
appeared, the sequence analysis showed no insert in the plasmid. After many unsuccessful
attempts, it was determined that outside help was needed with the ligation step. One hundred
microliters of 10 ng/µL DNA insert, and 5 µg of pCW plasmid was sent to Applied Biological
Materials Inc. (ABM, Inc.) who offered subcloning services. They sent back a full plasmid with
gene inserted.

Figure 12. LB-amp plate with a single large colony.
With a full expression vector, work on site-directed mutagenesis could start. Four
mutants were chosen, choosing no mutations in the transmembrane helix. Figure 13 shows a map
of all known mutations assumed to cause BCD (Kelly et al., 2011).
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Figure 13. Mutation sites along the CYP4V2 amino-acid chain believed to cause BCD. (Kelly
et al., 2011)
Mutations I111T, T325I, and H331P were all chosen from this map. Mutation F73L was
chosen from a paper detailing a research group studying 14 different Chinese families with BCD
(Yin et al., 2004). The first experiment with mutagenesis mutants F and I were chosen. All
necessary PCR reactants were added to the tube and run in the thermocycler. Product was
digested with just Dpn1, transformed into DH5α cells, and plated. The next day, there were no
F73L
cells on the plates. The next attempt, the same two mutants were used, using the Phusion HighFidelity PCR Master Mix. Using the new master mix, the plated cells had colonies, Figure 14.

I111T
Figure 14. Mutations F73L and I111T LB-amp plates with colonies present.
When grown and DNA sent off for sequencing, it was confirmed that no mutation was
present in the plasmid. To remove any parent plasmid in the PCR tubes, they were digested a
second time with DpnI, and new cells were transformed. The plates with I111T mutations had
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colonies. Sequencing confirmed there was no mutation present. The next two attempts at
mutagenesis attempted the T325I and H331P mutations using the same master mix and methods.
No colonies were observed on the plates.
For subsequent PCR attempts, only the forward primer was added to the tube. The
thermocycler was allowed to run for a few cycles, paused, and the reverse primer was added to
the tube, and the cycle was allowed to finish. When transformed and plated, there were a few
colonies for each mutation. When sequenced, there were mutations, insertions and deletions, but
none were of the desired mutation, so the product was discarded. Upon inspection of the primers,
it was discovered that there was an incorrect base pairing. The reverse primers of T325I and
H331P were redesigned to correct the pairings. When the new primers were diluted, all four
mutations were run using Phusion PCR kit. No colonies were present on the plates.
Instead of running all four mutants at the same time, each mutant was run individually
with their own Tm. Before plating, the concentration of DNA in the tube was verified using a
nanodrop. All concentrations were greater than 200 ng/µL indicating PCR was working. After
each mutant was cycled and plated, only the H331P mutation had any colonies. The other
mutations were replated using a longer outgrowth step for the transformation. Except for the
T325I mutation, all plates had colonies. When sent off for sequencing, a different company,
MCLab, was used, and DNA concentration was too low for sequencing. Using the DNA from the
previous plate, new cells were transformed and plated. Colonies were picked, and DNA was
extracted. The product was concentrated using the DNA Clean & Concentrator-5 kit, and
concentrations were still too low for sequencing. One more attempt at mutagenesis was made
with two tubes set up. One tube had exclusively the forward primer, and the other had the reverse
primer. After the first cycle, the two tubes were combined, and heated to denaturing
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temperatures. The tubes were cooled in a stepwise manner to promote reannealing. When plated,
no colonies were present. Site-directed mutagenesis was taken over by an undergraduate research
student as their main project.

Section 2.8 Discussion and Conclusions
Cloning was not an easy step to overcome in this project. Many attempts were made to
clone the 4V2 gene into the pCW plasmid with little success. To overcome this, ABM Inc. was
contacted to help with the subcloning, and they were able to produce a full vector. There were
similar issues with the subcloning step int pCW with another CYP project as well, so it is
suspected that the issue had to do with the pCW vector. After successful subcloning, the project
was able to move forward. Expression of the wild-type enzyme and site-directed mutagenesis
were the next steps.
Mutagenesis has proven difficult. Many different methods of PCR have been attempted
and the outcomes are usually no colonies or few colonies. If there are colonies, then the
sequencing results show that reactions failed to produce the mutation. The next step in the sitedirected mutagenesis is to use a Quickchange site-directed mutagenesis kit that was designed
specifically for this purpose.
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CHAPTER 3 – PROTEIN EXPRESSION AND PURIFICATION

In protein chemistry, chemists are not working with known substances in a beaker to
synthesize novel compounds for characterization. Protein chemists usually use host cells,
(bacterial, insect, or mammalian) for protein synthesis. A vector is designed with the gene of
interest and this is then transformed into the desired host cell. These cells are then grown in large
batches of media. This provides a large sample from which protein can then be harvested. With
the use of host cells, many other biomolecules are introduced into the sample. Cells synthesize
many other biomolecules and extracting just the molecule of interest is near impossible, and
purification methods are needed to isolate them. After isolation, chemists need additional
techniques to characterize the isolated material for qualitative and quantitative determinations
(Rosano and Ceccarelli, 2014; Manz et al., 2015).
Using classical analytical chemistry techniques such as gas chromatography (GC), liquid
chromatography (LC), nuclear magnetic resonance (NMR), mass spectrometry (MS), infrared
spectroscopy (IR), UV-visible spectroscopy (UV-Vis), and X-ray crystallography pose
challenges for biomolecular chemists. GC usually results in sample analytes destroyed and
requires the sample to be volatile for detection (Manz et al., 2015). Destroying research product
is non-ideal on the basis that acquiring quantifiable yields can be difficult, so preservation of
sample is preferred. IR and UV-Vis are insufficient in that biomolecules have large amounts of
functional groups and chromophores that give unambiguous identification near impossible. NMR
works by detecting spin active nuclei and for large biomolecules there can be many spin active
nuclei (Manz et al., 2015). For these techniques to be utilized, it is important to isolate the
particular protein of interest.
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For biochemists to use classical analytical methods modifications must be made. UV-Vis
is viable for molecules of interest that have very few chromophores that give signal in the visible
spectrum and in the area of protein. There have been many advances have been made to now
have NMR as a useful method be useful in determining the structure and molecular dynamics of
many macromolecules (Cavalli et al., 2007).

Section 3.1 Membrane Protein Expression and Extraction
Section 3.1.1 Protein Expression. Recombinant protein methods are used for human
proteins due to lack of abundance in their native environments. To obtain a sizable amount of
protein, methods in recombinant expression are used. The first process that must be complete for
expression is the choice in host cells. Escherichia coli (E. coli) is the most common method for
the expression of heterologous proteins (Rosano and Ceccarelli, 2014). There are several
advantages to using E. coli as a host cell. The growth of the cells is quick with a doubling time
somewhere in the range of 20-30 minutes (Rosano and Ceccarelli, 2014). Another benefit is the
quick and easy methods to transform the cells with the foreign DNA. Plasmid transformations
can be as quick as 30 minutes. E. coli cells also have a high cell density, so a lot of cells can be
grown with the protein of interest in a minimal amount of media (Rosano and Ceccarelli, 2014).
All of this combined makes the use of E. coli seem to be the cure all for protein expression but
there are some problems associated with their use, especially for membrane proteins (Rosano and
Ceccarelli, 2014; Delar et al., 2015).
For the expression of eukaryotic membrane proteins there are circumstances that make E.
coli a less than suitable host (Rosano and Ceccarelli, 2014). If the protein in question has any
post-translational modifications, the host cell may not be able to reproduce the modifications
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because of a lack of modification capabilities. Translational capabilities are also variable from
host organisms. What could be a common codon encoding an amino acid in human cells could
be a rare codon in the chosen organism. These rare codons can have a serious impact on the
expression levels (Delar et al., 2015). After membrane proteins have been expressed, these
proteins must then be inserted into the membrane of the cell. There are differences in the lipid
bilayer and transport mechanism that could lead to the protein aggregating instead of being
enzymatically active (Delar et al., 2015). Further, expressed membrane proteins can be toxic to
their host cells. With most membrane proteins acting as transport systems and membrane
channels, the introduction of increased pores and channels can change the influx and efflux of
nutrients and other intracellular chemistry of the cells (Delar et al., 2015). This can disrupt
metabolic processes leading to detrimental effects. To combat all of these factors, various strains
of E. coli have been developed to reduce the negative effects and give suitable expression yields
(Rosano and Ceccarelli, 2014; Delar et al., 2015).
Section 3.1.2 Protein Extraction. Once expressed in a new host cell, membrane proteins
must be extracted. With cell soluble proteins, this is a simple step in which the cells are lysed
open and the protein is extracted through various purification methods. Membrane proteins are
embedded in the membrane, and if the cells are lysed, then the proteins of interest would stay
associated with the cell membrane. These must be extracted from the cell membrane using
detergents that provide similar conditions to those found in the bilayers. Using detergents,
researchers can mimic the environment of the lipid bilayer, preserving protein structure and
functionality. Figure 15 is a cartoon depiction of a protein embedded in the lipid bilayer, and
protein enveloped in detergent. Most detergents have a similar structure with two main groups, a
hydrophobic tail and a hydrophilic head group. This gives the detergent molecule an amphipathic
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nature which allows it to interact with both the solvent and the nonpolar surfaces of the protein.
In solution, detergent monomers surround the protein associating with each other and binding to
the protein surface at concentrations equal to the detergents critical micelle concentration (CMC)
(Delar et al., 2015).

Figure 15. Cartoon depiction of membrane-bound protein, and membrane protein isolated with
detergent molecules (Delar et al., 2015).
Section 3.2 Chromatography
Section 3.2.1 Principles of Chromatography. Chromatography in the simplest of forms
has an analyte molecule in the mobile phase interacting with the stationary phase. Separation
takes place because of the different interactions between the mobile phase and a stationary phase.
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Depending on the extent of interactions between the mobile and stationary phase, molecules will
elute from the stationary at different times leading to separation of molecules (Manz et al., 2015).
Analyzing samples by chromatography is most commonly used for the separation,
isolation, and purification of biomolecules. When using cell host cells for the procurement of
usable quantities of protein, other proteins and cell components are dispersed with analyte of
interest. These extra components must be separated from the sample and can be done so through
many chromatographic methods. The two discussed here will be affinity chromatography and
ion-exchange chromatography (Manz et al., 2015).
Section 3.2.2 Affinity Chromatography. Affinity chromatography works on the
principle of high-specificity interactions. Recombinant proteins usually have a poly-histidine tag
that interacts with a metal ion, cobalt or nickel, incorporated during gene design. There are four
general stages that affinity chromatography can be separated into: 1. Sample introduction, 2.
Adsorption, 3. Washing, and 4. Desorption. In stage 1, impure sample is loaded onto the column
that has been packed with a solid phase of metal ions, antibodies, or protein specific ligands. In
stage 2, biomolecules of interest that have an affinity for the solid phase are adsorbed and the
impurities that do not have affinity flow through the matrix. Stage 3 has the bound sample
washed with different buffers that elute off the weakly bound impurities. Stage 4, desorption, is
achieved through various means. pH increase, salt content increase, of introducing a ligand with
higher specificity. The introduction of an elution factor competes for binding to the solid phase
causing bound analyte to elute off the column. For nickel-affinity chromatography, the elution
factor is typically imidazole or histidine.
Section 3.2.3 Ion-Exchange Chromatography. Ion-exchange chromatography separates
using a difference in charge between the mobile phase with target analyte and a stationary phase
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of porous, functionalized resin beads. There are two main types of ion exchangers: anionic
exchangers and cationic exchangers. In anion exchange, the resin beads are coated in diethyl
aminoethyl (DEAE) functional groups which are positively charged. Cationic exchangers are
coated in carboxy methyl (CM) functional groups that are negatively charge. Choosing a resin
depends on the pH of the mobile phase used for separation. Using a mobile phase with a high pH
will cause more deprotonation of target analytes causing a negatively charged species. In this
case, the resin of choice would be the DEAE beads because the negatively charged molecules
would bind in the pores of the positively charged resin beads. The opposite holds true for
positively charged molecules and CM beads. Choosing an appropriate mobile phase is important,
as it should be noted that the loading capacity is dependent on the charge of the resin. Choosing a
mobile phase that has too high or low of a pH can be detrimental to the resin. For the case of
DEAE beads, choosing a mobile phase with a pH greater than 8 would cause the amino group to
be deprotonated and the beads would no longer bind negatively charged molecules. (Manz et al.,
2015).
Proteins are amphoteric in nature with both positive and negatively charged groups. The
combination of all these groups charges gives the protein its overall charge. At some point along
the pH spectrum, a protein is completely neutral, this is called the protein’s isoelectric point (pI).
When operating at pH values close to a proteins pI, there is minimal absorption to the beads.
Increasing or decreasing the pH by one or two values would vastly increase the charge a protein
exhibits, increasing binding greatly. Buffer concentrations should be kept as low as possible to
avoid competitive binding (Manz et al., 2015).
As in affinity chromatography, there are four main stages to ion-exchange: 1. Sample
introduction, 2. Adsorption, 3. Washing, and 4. Desorption. Desorption of analyte molecules is
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done through increasing the salt concentration or changing the pH of the buffer. Increasing the
salt concentration, increases the number of ions in solution. The increase in ions creates new
competitive binding for the beads. Weaker bound proteins (protein misfolding or incomplete
proteins) elute first because of the difference in net charge from correctly folded proteins. The
other method of a pH gradient works in a similar fashion. Changing the pH causes the net charge
of the protein to change and decrease the interactions with the resin, or it neutralizes the resin
also decreasing the interactions eluting the protein (Manz et al., 2015).

Section 3.3 Sodium Dodecyl-Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
The main principle driving the separation in SDS-PAGE is protein size. The introduction
of the SDS coats it in an evenly distributed negative charge, eliminating the intrinsic charges of
proteins, giving all proteins the same mobility. Another additive in SDS-PAGE is βmercaptoethanol (2-mercaptoethanol), which is a thiol-reducing agent. When introduced,
disulfide bonds are broken, eliminating the tertiary structure of the proteins. Similar to standard
gel electrophoresis, a molecular weight ladder runs in tandem that gives a standard set of
molecular weights for visual verification. After the chamber finishes running, the entire gel must
be stained to visualize any banding that may appear. A staining solution of Coomassie brilliant
blue is usually poured over the entire gel, heated, and allowed to sit and stain .

Section 3.4 Carbon Monoxide Difference Assay
One method used to determine not only the quantity of a cytochrome P450 protein but
also the quality of protein in a purified cytochrome P450 sample or cellular matrix is the use of a
carbon monoxide (CO) difference assay. The main principle behind the CO difference assay is
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the binding of CO to the heme of hemeproteins causes a wavelength maximum at 450 nm (Soret
peak) in the energy spectrum. This assay is mainly used in the characterization of recombinant
P450 proteins as this characteristic shift is how they earned their name. It also shows the
integrity of the protein over time. As protein degrades in solution, a shift in the Soret peak from
450 nm to 420 nm indicates protein integrity decreasing. One of the problems with this though is
that it does not distinguish between hemeproteins in solution. Should there be multiple
cytochrome P450s, no difference would be seen (Guengerich et al., 2009).

Section 3.5 Methodology
Section 3.5.1 Media Preparation. To prepare a 100 mL solution of LB media, into a
medium-sized beaker, 1 gram of Tryptone, 0.5 g yeast extract, and 1 g of sodium chloride (NaCl)
were added. The volume was brought to 100 mL with water. The top of the beaker was sealed
with aluminum foil and a piece of autoclave tape. The beaker was placed into the autoclave and a
liquid cycle was run. Once the cycle completed, the beaker contents were allowed to cool to
room temperature before storing in cold storage for later use.
To prepare TB media, to a 2 L flask, 50.4 g of prepared Terrific Broth powder was
supplemented with 4 mL of 100% glycerol. The volume was brought to 1000 mL, sealed with
aluminum foil. The flask was run through a liquid autoclave cycle and allowed to cool to room
temperature before placing in cold storage for later use.
Section 3.5.2 Buffer Preparation. All purification buffers started with a basic Tris
buffer of pH 8.0. This buffer was prepared in a large storage container where 60.57 g of Trizma
and 450 mL of water were added. The pH of the solution was brought to ~8.0 and then diluted to
500 mL. This was used to prepare all other buffers. All purification buffers from the Tris buffer
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are pH adjusted to 8.2 after being prepared. In Table 5, the purification buffer components are
listed.

Table 5. Reagents Needed for Purification Buffers.
Tris Buffer
Glycerol
Buffer Name
(mL)
(mL)
Resuspension Buffer
250
Ni-NTA Wash Buffer
50
Ni-NTA Elution Buffer
50
Ion Exchange Wash
25
Buffer
Ion Exchange Elution
50
Buffer

Water
(mL)
50
50
50

NaCl
Imidazole
(g)
(g)
200
8.77
N/A
400
8.77
0.34
400
1.46
6.8

50

425

N/A

N/A

50

400

14.61

N/A

Section 3.5.3 Cell Transformation. To start the transformation, the plasmid and DNA
need to be ligated. To a PCR tube, 2.5 µL of Anza T4 DNA Ligase Mastermix, 6 µL of DNA,
and 2 µL of empty plasmid was added. This was allowed to incubate on the benchtop for at least
an hour, with an overnight incubation preferred. To 50 µL of DH5 competent cells, 5 µL of
ligation mix was added. This new mixture was allowed to incubate on ice for thirty minutes.
After the incubation period, the cells were heat shocked at 37℃ for thirty to forty seconds in a
hot water bath. After heat shock, the cells can be chilled back on ice for two minutes, or 500 µL
of LB media with no antibiotic can be added. If placing on ice, incubate for two minutes and then
plate onto a prepared LB-Amp plate. Glass beads are added, and the plate is swirled around to
deliver a thin layer of cells. The plate was placed inside the incubator overnight. If doing an
outgrowth step, after adding the 500 µL of LB media, the cells are allowed to incubate at 37℃ in
the incubator for at least an hour. After incubation, the cells were centrifuged down. All but 50
µL of solution is removed from the Eppendorf tube and the cells are resuspended in the
remaining media. The resuspended cells are plated in the above method.
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Section 3.5.4 Expression of CYP4V2. After sequence verification, 1 µL of plasmid from
Plasmid Preparation was transformed into the JM109 cell line. The next day, a single colony of
transformed cells were picked and grown in 100 µL of LB media with ampicillin. This starter
culture of cells is distributed between 2 L of prepared TB media with ampicillin. The cells were
grown shaking at 37℃. After an hour and a half, the OD600 is measured. Cells need to grow to at
minimum 0.4 and at maximum 1.4 AU before induction. This allows to enter peak logarithmic
growth. To induce, 0.22 g/L of β-D-1-thiogalactopyranoside (IPTG) and 0.22 g/L
aminolevulenic acid (ALA) was added to each liter of cells. The temperature of the incubator
was reduced to 32℃ and the cells were set to shake for three days.
Once cells have been expressed for three days, distribute the TB media between four 400
mL centrifuge tubes. Centrifuge the cells at 5000 rpm for 15 minutes. Decant off the upper liquid
layer and repeat until all growth media has been centrifuged. Resuspend the pellet with minimal
resuspension buffer and either decant into a 50 mL Falcon tube for cold storage or proceed onto
protein extraction.
Section 3.5.5 Protein Extraction. Place resuspended cells in an appropriately sized
beaker and place into a bed of ice. Take the cells on ice to a probe sonicator and position the tip
of the probe near the bottom of the beaker, but not resting on the bottom. Sonicate the cells for
thirty seconds, and let them rest for thirty seconds, alternating between the two for at least three
minutes. Cells should take on a darker color. Remove the probe, place a stirring rod into the
beaker, and place into a shallow glass dish on a magnetic stirrer surrounded by ice. While
stirring, add in enough Cymal-5 and Triton X-100 to reach the CMC for both. Example
calculation for a dry detergent (Cymal-5) shown in the equation below.
3.2 mM x ____ mL sample x 494.5 g/mol = _________/1000/1000 = ______________ g cymal-5
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Allow the mixture to stir for an hour before splitting evenly into small centrifuge tube.
Place the tubes into the centrifuge and spin at 20,000 rpm for fifteen minutes. Remove and save
the upper liquid layer. This contains the now solubilized protein ready for purification.
Section 3.5.6 Protein Purification. Using the BioRad Biologic LP chromatography
instrument, connect a purification column with Ni-NTA beads to the delivery line. Flush all lines
with water. In order, connect lines A, C, D, and E to the lysate, 50 mL of resuspension buffer, 35
mL of wash buffer, and 35 mL of elution buffer. Using above equation, add the appropriate
amount of Cymal-5. Triton X-100 is not added. Using a small pipette, add resuspension buffer to
the column to equilibrate the beads. Using the “4V2” method in the instrument, begin the
purification, and press run on the fraction collector. Allow the instrument to run through lysate
and all the buffer. Once finished, either visually inspect the collected fractions, or using the LP
Data View™ MS Software, chose the fractions that eluted off in the latest buffer. Remove the
fractions and purge the column and lines with DI water.
Dilute these fractions 10x, if using fractions from the wash buffer, or 5x, if using
fractions from the elution buffer. Dilution is done with ion-exchange wash buffer. Once diluted,
place line C into the diluted protein, and lines A and B into 50 mL of wash buffer and 25 mL of
elution buffer, respectively. All buffers, including dilution buffer, should have detergent added to
them. Run the “4V2 DEAE” method to begin the purification. Collect the fractions like above.
Section 3.5.7 Obtaining an Absolute Spectrum. After purification, an absolute
spectrum is taken to give a general idea of protein purification and to see if there is P450
enzyme. Using 750 µL of elution buffer with detergent added, autozero and baseline the UV-Vis.
After baselining, add anywhere from 5-30 µL of protein sample, depending on visual
concentration. Scan the sample at a wavelength range of 750-250 nm.
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Section 3.5.8 SDS-PAGE. Once the protein sample has been purified, verification of
purity is needed. To start, fractions are collected that are believed to have the purest protein.
Remove 20 µL of protein fraction and place into a small Eppendorf tube, keep in mind which
fraction is which. To the Eppendorf tubes, add in 20 µL of loading dye with β-mercaptoethanol.
Prepare an Eppendorf tube with a protein ladder in the same manner. The gels come with a comb
and a piece of tape that both must be removed. Remove the tape located at the bottom of the gel
before applying voltage to the chamber. The comb is inserted in the top and must be removed
gently as to not disturb the well shapes. Remove the gel runner from the container and place the
gel into the runner, ensuring a secure seal is made with the clamps. Place the gel runner into the
container and fill with 1x SDS-PAGE running buffer making sure the electrical contacts are
covered with buffer. Load the protein ladder into the first well, and the analytes in subsequent
wells. Set the voltage to 210 and allow to run. Make sure there are visible bubbles coming from
the bottom of the gel. Allow the gel to run until the visible bands reach the bottom of the gel.
Once complete, remove the gel runner, unclamp the gel and remove. Crack the four corners of
the plastic housing, exposing the gel. Remove the gel with a little bit of water and place into a
container for staining.
To the plastic container, add in an arbitrary amount of Coomassie staining solution to
cover the gel. Place into a microwave and run for 20-30 seconds to allow the gel to stain. Pour
the excess stain back into the bottle. Cover the gel with water, and microwave again for two
minutes. Repeat the process of heating and pouring off excess liquid until the bands on the gel
can be visualized. Gel may need to be moved to a light box to help visualize the banding.
Qualitative protein purity can be determined by the number of bands present in each lane.
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Section 3.5.9 CO Difference Assay. To determine if there is active P450 protein in the
purified fractions, a CO Difference Assay is used. Place 750 µL of protein fraction into a cuvette
with a few crystals of sodium dithionite, place into the UV-Vis instrument and autozero, then
baseline with the sample. Remove the cuvette and add in 50 bubbles of CO. Place the cuvette
back in the instrument, autozero, and scan over a range of 500-350 nm. Repeat the scan every
five minutes until an increase in absorbance is no longer seen.

Section 3.6 Results
With the plasmid from ABM, Inc. JM109 cells were transformed with the DNA and
plated. For the first expression, a colony was picked from the plate and a starter culture was
grown. The culture was split between 2 L of TB media. OD600 was checked over the course of a
few hours waiting for an absorption value of 0.4. At OD600 = 0.156 the cells were induced. This
was too early of an induction; cells were not in the appropriate stage of growth. After the threeday growth the cells were pelleted and resuspended in buffer, with a pH of 7.4. The cells had the
appearance of a light coffee color. After detergent extraction, the lysate appeared a bright orange
color. Once added to the column, there was a dark red band present at the top when protein
loading finished. Once the resuspension buffer started to run, the protein started to crash out.
After the resuspension, wash, and elution run, white, flocculant material was present indicating
crashed protein. Figure 16 shows the pelleted cells, lysate, and banding on the column.
For the second purification, the cells were allowed to grow to an OD600 > 0.8. The
pelleted cells had a much darker appearance. There was a darker brown banding around the
outside of the pellet indicating more present protein in the cells. During the resuspension step of
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purification, all protein eluted off the column. Unlike previous preparations, the third preparation
bound throughout the entire column. Similarly, protein eluted off in the wash buffer.

Figure 16. Pictures from the purification process. From left to right, pelleted cells after
centrifugation, lysate decanted after detergent extraction, banding present on the affinity
column after protein loading.
This wash elution was moved to the ion-exchange column for further purification. For the
column matrix, a CM column was used. After a 10x dilution, no binding was present on the
column. Using Expasy Protparam, it was discovered that the pI point was 7.26. Using buffers at
pH 7.4 not only was not conducive to CM media, but also being at the pI point was causing
protein to aggregate. For further purifications, the pH of buffers was adjusted to 8.2, and ionexchange media was changed to DEAE.
Present in all three preparations, after the final centrifugation, there was a dark band
present at the top of the pelleted cells. Protein was still present in the cells and needed to be
extracted. Preparation four addressed the extraction issue by adding in Triton X-100. When
added alongside Cymal-5, the banding at the top of the cells is less prevalent and the color
difference in lysate is drastic, Figure 17.
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Figure 17. Differences in lysate color before and after addition of Triton X-100
This was purified using affinity and ion-exchange chromatography. Banding was present
on the DEAE beads, and protein eluted off in the wash buffer. Using a portion of saved fractions
from the affinity and ion-exchange purifications, an SDS-PAGE was run to give a qualitative
purity, Figure 18. Lane 1 is the protein ladder, lanes 2 and 3 are fractions from the affinity
column, and lanes 4, 5, and 6 are from the ion-exchange column.

Figure 18. SDS-PAGE gel showing the change in purity from affinity chromatography to ionexchange chromatography. Red arrow points to band representing CYP4V2.
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The purity from affinity to ion-exchange is noticeable, only three main bands are present
in the later lanes with multiple bands present in the first two protein lanes. For a more
quantitative approach to determining purity, an absolute spectrum was obtained from the ionexchange fraction. Figure 19 shows the spectrum obtained. The fractions from the ion-exchange
column were concentrated down to ~500 µL, and the concentration was determined to be 306
µM or 17.7 mg/mL. This protein was used to set up a crystal tray. Before the concentrated
protein could be used further, it lost all activity. Possibly because of concentrating all sample
together leading to aggregation. Preparation number five was purified all the way through ionexchange. A decreased yield of 0.87 mg/mL was obtained from this purification. At this point,
the glycerol stock prepared from the first purification was a few months old and with the next
starter culture, a fraction was saved to create a new glycerol stock.

Figure 19. UV-Vis spectrum of protein in solution from ion-exchange chromatography. Soret
peak at 400 nm.
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With each previous purification, the nickel was being stripped from the beads. The bright
blue color was slowly dulling, and binding was become more diffuse through the column. The
idea was had to change from a highly basic Tris buffer system to a more acidic phosphate
system. Buffer recipes now had 500 mM phosphate and a pH adjusted to 6.5. When purifying a
new preparation, pellets were resuspended in the new buffer system. When loading onto the
column, no binding was present. The phosphate system was abandoned, and resuspension was
switched back to Tris. Since the nickel beads were losing their color, they were recharged using
nickel sulfate. Before the decision to switch back to Tris was made, a preparation was already
resuspended in phosphate buffer. During the affinity purification, the column was equilibrated
with pH 8.2 Tris buffer, and the pH 6.5 resuspended protein was loaded. There was very diffuse
binding on the column, when the pH 8.2 resuspension buffer started loading, protein crashed on
top of the column. Letting the method run through elution proved useful in that two 2 mL
fractions of protein eluted in the elution buffer. These two fractions were purified further, and a
protein concentration of 86 µM, or 4.98 mg/mL. A full spectrum graph was obtained, and protein
was stored in the fridge for stability studies. The next day, to assess longevity, another full
spectrum scan was performed, and protein concentration dropped, Figure 20. This is a sign of
stability issues. One more preparation was expressed and purified and again an overnight
difference in CO activity showed that there was a decrease in activity.

Section 3.7 Discussion and Conclusions
The first expression with the early induction time was a human error and could have
easily been prevented. All subsequent expressions were induced at 0.4 ≤ OD600 ≤ 1.4. This
changed the pellets from just coffee colored to have a dark ring around the edges and dappled
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with the darker portions. Purification was the main struggle in this project. Many times, the
protein did not bind to the column, or if it did bind it eluted in the resuspension buffer. Except
for one case, protein banding was never present. All bindings were very diffuse and weak. To try
and increase binding the pH of the buffer was changed. This seemed to allow protein binding to
strengthen, and protein stopped crashing on top of the column. The downside being that the
nickel column was stripping. Only a few purifications could be done before the column needed
to be recharged. To try and offset the stripping, the pH was changed to an acidic buffer made
from phosphate. This decreased stripping but again caused protein binding to weaken
significantly.
The method that worked best for purification was using the Tris base with a pH of 8.2.
The column will have a life of 3-4 purifications before it needs to be recharged due to stripping.
After the purification process, the work time is short due to stability issues. Any subsequent
testing needs to be done quickly. Changes that I would suggest helping with stability issues
would be to increase the glycerol concentration in the ion-exchange elution buffer. This may lead
to protein stability.

Figure 20. Contrasting absolute spectra showing a decrease in protein stability.
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CHAPTER 4 – X-RAY CRYSTALLOGRAPHY

Section 4.1 Membrane Protein Crystallography
In 2015, the Protein Data Bank had close to 100,000 protein structures logged. Of the
100,000, approximately 1% of the structures were those of membrane proteins (Delar et al.,
2015). Although the number of solved membrane proteins is small, about 30% of genes encode
for membrane proteins (Delar et al., 2015). The main problems associated with membrane
protein crystallography are: 1. acquiring sufficient quantities of purified protein and 2. obtaining
high-quality crystals for diffraction (Delar et al., 2015). The first problem was discussed in
Chapter 3 Section 3.1.1 and will not be discussed here.
In the case of soluble protein samples, proteins not embedded in the membrane, the
dominating factor of crystallization are the protein-protein interactions. In the case of membrane
proteins, the use of detergent in the extraction introduces protein-detergent and detergentdetergent interactions, while still having protein-protein interactions (Delar et al., 2015). Delar et
al. believe that the more effort that is placed in finding a suitable, mild detergent is more
important than optimizing other parameters of crystallography. In its most simple form, a
crystallization experiment involves a solution of precipitant is mixed with a solution containing a
purified protein-detergent complex. The precipitant solution is a mix consisting of a precipitant,
salt, and buffer (Delar et al., 2015). The combination of the two solutions causes the drop to
enter a state of supersaturation. Once supersaturated, the complex can either aggregate and fall
out of solution or crystallize. The most common, and successful method for obtaining high
quality crystals is the vapor diffusion method (Delar et al., 2015).
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As stated above the precipitant solution is a mix of three different components to aid in
the crystallization process: precipitant, salt, and buffer. There are two categories that precipitants
are divided into: 1. organic solvents, and 2. long-chain polymers (Delar et al., 2015). Organic
precipitants reduce the electrostatic interactions leading to a decrease in ionic compound
solubility (Delar et al., 2015). When the concentration of organic precipitants becomes too high,
they can denature proteins. The second precipitants are a group of long-chain polymers, with the
most common being poly-ethylene glycols (PEGs). Precipitants using PEGs are acting through
the volume-exclusion effect (Delar et al., 2015). The second component of precipitant solutions,
salts act by modifying the solubility of proteins. While the mechanism of action is unknown, it is
speculated that salts cause interactions between the ions, the protein structure, and water. The
third component, buffers, changes the pH of the solution which then affects the electrostatic
interactions between the protein-detergent complexes (Delar et al., 2015). At a pH equal to the pI
of the protein, solubility decreases. This creates a harsh environment for crystallization, while pH
values close to the pI has shown to be optimal conditions for crystallization (Delar et al., 2015).
In the vapor diffusion method, small quantities of purified protein samples are mixed in
equal proportions with a crystallization solution forming a drop. This drop is now half protein,
half crystallization solution. This drop is then either placed in a well, sitting-drop method, or
attached above the well, hanging-drop method, and the chamber is then sealed from the outside
environment, Figure 21. Volatile components in the drop will evaporate into the chamber and
diffuse into the well. This creates a system at equilibrium. At the state of equilibrium, there are
different phases the drop can manifest. Crystallization with detergents can crystallize protein,
aggregate compounds into micelles, or it can separate into regions being detergent rich or poor.
Today, there are readily available crystal screening kits that have preset precipitant solutions that
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have proven to crystallize complexes, and act as a starting point for any crystallographer. Once
an initial hit has been discovered, the conditions of the well can be modified in small increments
to optimize crystal growth, producing large crystals with few imperfections. Multiple rounds of
optimization may be performed to find the best conditions. (Delar et al., 2015).

Figure 21. Hanging-drop (left) and Sitting-drop (right) method for crystallization.
Section 4.2 Methodology
Section 4.2.1 Concentrating Protein. Fractions with the purest protein content were
concentrated for binding assays and crystallographic setups. The fractions were selected that
were determined to be the purest from the SDS-PAGE gel. The fractions were transferred into an
Amicon Ultra filter tube with a 50 KDa cuttoff. The tube was centrifuged the tube at 5000 rpm
for twenty minutes. Roughly 1 mL of flowthrough was kept and the rest discarded. Repeat the
concentration with other fractions purified, saving some fractions to not concentrate. This
process was repeated with other fractions purified. Once fractions were concentrated to ~200 µL,
the molar concentration of the protein was determined.
Section 4.2.2 Determining Molar Concentration. Using the UV-Vis, the instrument
was baselined with 750 µL of saved flowthrough, scanning at a wavelength range of 500-350
nm. 5 µL of concentrated protein was added to the cuvette, pipetting up and down, gently, a few
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times to mix the solution. The instrument was scanned to obtain the absorbance at 400 nm. Using
Beer’s Law, the concentration of the protein was calculated by rearranging the equation and
dividing the absorbance by the product of the extinction coefficient and path length. Absorbance
was taken from the UV-Vis scan, and the extinction coefficient is given to be 0.1 µM-1cm-1 if
using the absolute spectrum peak for the heme. This provides the concentration after dilution. To
determine the protein concentration before dilution, multiply the concentration by the dilution
factor. To determine dilution factor, divide the total cuvette volume by the volume of protein
sample added.
Section 4.2.3 Crystallographic Setups. Hampton Research Crystal Screen 1 and 2 was
used to set up the 96 reagents into a reservoir tray. 75 µL of each reagent was pipetted into a
crystal screen tray, making sure to keep the same positioning of reagents. Then, 0.5 µL of
purified protein sample was pipetted into the sample well, and then 0.5 µL of each reagent was
placed into the sample well. The screening tray was covered tightly and placed into a 19℃
incubator. Each sample well was checked every few days and the appearance of the sample well
was described.
A crystal hit can be optimized from the initial conditions using the optimization tool on
the Hampton Research website. The optimization tool provides all relevant volumes and
concentrations for a 24-well crystal tray. For the optimized tray, the indicated volumes of
reagents into the sample well were pipetted. On a cover slide, 0.5 µL of purified protein and 0.5
µL of well reagent were placed. The edge of the sample well was covered with grease or another
sealant and inverted over the well to seal airtight. This tray was also incubated, and progress was
checked every few days.
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Section 4.3 Results and Conclusions
Using the concentrated mentioned above in section 3.6, an initial crystal screen was
performed. Of the 96 wells, only one presented with a crystal hit, well H3. The well reagents
were 0.2 M magnesium chloride hexahydrate, 0.1 M Tris pH 8.5, and 3.4 M 1,6-hexanediol.
These conditions produced a single crystal, Figure 22. An optimized plate has been designed
around these conditions. No recent expression has yielded suitable quantities of protein for
preparation.

Figure 22. Picture of the crystal well (left) and an up-close picture of the initial crystal hit
(right). Red arrow indicating the position of the crystal in the well.
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CHAPTER 5 – FUTURE DIRECTIONS
For the future direction of this project, all four mutants need to be mutated through site
directed mutagenesis and sequence verified. Once they have been obtained, the expression
method for the wild-type enzyme may need to be modified. Modifications may be slight, or a
different method may need to be determined.
For the wild-type purification method, fixing the stability issues is the next project. This
may be achieved through increasing the glycerol content in the elution buffers or finding a more
stable buffer system that can better accommodate the protein’s instability. Other detergents
beside Cymal-5 and Triton-X-100 may be required. After stabilization, optimization of the
crystal screen can happen. The plate has been designed, but protein purity and concentrations
need to be obtained before a plate can be made.
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